Rebecca Marlow

1310

Citations

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Keywords

RC0254 Neoplasms. Tumors. Oncology (including Cancer)

Fingerprint

Dive into the research topics where Rebecca Marlow is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

20 Article

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
Harvey-Jones, E., Raghunandan, M., Robbez-Masson, L., Magraner-Pardo, L., Alaguthurai, T., Yablonovitch, A., Yen, J., Xiao, H., Brough, R., Frankum, J., Song, F., Yeung, J., Savy, T., Gulati, A., Alexander, J., Kemp, H., Starling, C., Konde, A., Marlow, R. & Cheang, M. & 19 others, Proszek, P., Hubank, M., Cai, M., Trendell, J., Lu, R., Liccardo, R., Ravindran, N., Llop-Guevara, A., Rodriguez, O., Balmana, J., Lukashchuk, N., Dorschner, M., Drusbosky, L., Roxanis, I., Serra, V., Haider, S., Pettitt, S. J., Lord, C. J. & Tutt, A. N. J., Apr 2024, In: Annals of Oncology. 35, 4, p. 364-380 17 p.
Research output: Contribution to journal › Article › peer-review

Open Access
20 Citations (Scopus)
CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
Cheung, A., Chenoweth, A. M., Quist, J., Sow, H. S., Malaktou, C., Ferro, R., Hoffmann, R. M., Osborn, G., Sachouli, E., French, E., Marlow, R., Lacy, K. E., Papa, S., Grigoriadis, A. & Karagiannis, S. N., 11 Jul 2022, In: Cancers. 14, 14, 21 p., 3361.
Research output: Contribution to journal › Article › peer-review

Open Access
File
9 Citations (Scopus)

158 Downloads (Pure)
3D functional genomics screens identify CREBBP as a targetable driver in aggressive triple-negative breast cancer
Peck, B., Bland, P., Mavrommati, I., Muirhead, G., Cottom, H., Wai, P. T., Maguire, S. L., Barker, H. E., Morrison, E., Kriplani, D., Yu, L., Gibson, A., Falgari, G., Brennan, K., Farnie, G., Buus, R., Marlow, R., Novo, D., Knight, E. & Guppy, N. & 22 others, Kolarevic, D., Susnjar, S., Milijic, N. M., Naidoo, K., Gazinska, P., Roxanis, I., Pancholi, S., Martin, L. A., Holgersen, E. M., Cheang, M. C. U., Noor, F., Postel-Vinay, S., Quinn, G., McDade, S., Krasny, L., Huang, P., Daley, F., Wallberg, F., Choudhary, J. S., Haider, S., Tutt, A. N. & Natrajan, R., 15 Feb 2021, In: Cancer Research. 81, 4, p. 847-859 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
11 Citations (Scopus)
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Zatreanu, D., Robinson, H. M. R., Alkhatib, O., Boursier, M., Finch, H., Geo, L., Grande, D., Grinkevich, V., Heald, R. A., Langdon, S., Majithiya, J., McWhirter, C., Martin, N. M. B., Moore, S., Neves, J., Rajendra, E., Ranzani, M., Schaedler, T., Stockley, M. & Wiggins, K. & 41 others, Brough, R., Sridhar, S., Gulati, A., Shao, N., Badder, L. M., Novo, D., Knight, E. G., Marlow, R., Haider, S., Callen, E., Hewitt, G., Schimmel, J., Prevo, R., Alli, C., Ferdinand, A., Bell, C., Blencowe, P., Bot, C., Calder, M., Charles, M., Curry, J., Ekwuru, T., Ewings, K., Krajewski, W., MacDonald, E., McCarron, H., Pang, L., Pedder, C., Rigoreau, L., Swarbrick, M., Wheatley, E., Willis, S., Wong, A. C., Nussenzweig, A., Tijsterman, M., Tutt, A., Boulton, S. J., Higgins, G. S., Pettitt, S. J., Smith, G. C. M. & Lord, C. J., Dec 2021, In: Nature Communications. 12, 1, 3636.
Research output: Contribution to journal › Article › peer-review

Open Access
220 Citations (Scopus)
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
Hoffmann, R. M., Mele, S., Cheung, A., Larcombe-Young, D., Bucaite, G., Sachouli, E., Zlatareva, I., Morad, H. O. J., Marlow, R., McDonnell, J. M., Figini, M., Lacy, K. E., Tutt, A. J. N., Spicer, J. F., Thurston, D. E., Karagiannis, S. N. & Crescioli, S., 1 Jun 2020, In: Scientific Reports. 10, 1, p. 8869 8869.
Research output: Contribution to journal › Article › peer-review

Open Access
File
14 Citations (Scopus)

86 Downloads (Pure)

Towards in vitro oncology trials: drug testing in cultured patient derived tumour organoid cultures
Tutt, A. (Primary Investigator) & Marlow, R. (Co-Investigator)
NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research
1/09/2016 → 30/04/2020
Project: Research
Towards in vitro oncology trials: drug testing in cultured patient derived tumour organoid cultures.
Tutt, A. (Primary Investigator) & Marlow, R. (Co-Investigator)
1/09/2016 → 31/08/2019
Project: Research
Characterization of the immune microenvironment present in murine models of triple-negative breast cancer
Tutt, A. (Primary Investigator), Hayday, A. (Co-Investigator), Cezar, F. (Co-Investigator) & Marlow, R. (Co-Investigator)
Breast Cancer Campaign
1/01/2015 → 1/01/2016
Project: Research
Validation of GPR89 as a drug discovery target for triple-negative breast cancer
Tutt, A. (Primary Investigator), Marlow, R. (Co-Investigator) & academic, A. (Co-Investigator)
1/06/2014 → 31/05/2015
Project: Research

Rebecca Marlow

Personal profile

Expertise related to UN Sustainable Development Goals

Keywords

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models

3D functional genomics screens identify CREBBP as a targetable driver in aggressive triple-negative breast cancer

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Towards in vitro oncology trials: drug testing in cultured patient derived tumour organoid cultures

Towards in vitro oncology trials: drug testing in cultured patient derived tumour organoid cultures.

Characterization of the immune microenvironment present in murine models of triple-negative breast cancer

Validation of GPR89 as a drug discovery target for triple-negative breast cancer

Rebecca Marlow

Personal profile

Expertise related to UN Sustainable Development Goals

Keywords

Fingerprint

Collaborations and top research areas from the last five years

Research output

Projects